Targets › GUCY2D
1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.
Catalyzes the synthesis of cyclic GMP (cGMP) in cone and rod photoreceptors, playing an essential role in phototransduction. Restores cytoplasmic cGMP levels, thereby returning photoreceptor cells to their dark-adapted state via a Ca(2+)-dependent negative feedback loop. (UniProt, Q02846)
Open in Phaseline: the race on GUCY2D, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Atsena Therapeutics | ATSN-101 Gene therapy for GUCY2D mutations | GUCY2D | Phase 1 | Leber Congenital Amaurosis | May 2027 |
Leber Congenital Amaurosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.